Following the FDA’s advice, Omeros has hit the brakes on a mid-stage human trial of its Huntington’s disease treatment in light of data from a separate animal study, news that tanked the biotech’s share value.

…read more

Source: Omeros halts a Phase II Huntington’s trial over alarming rat results


0 No comments